Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kensey Nash sees broad application for biomaterials

This article was originally published in Clinica

Executive Summary

Kensey Nash has maintained a compound annual growth rate of 60% since its IPO in 1995, Joe Kauffmann, president and CEO of the company, told a recent UBS Warburg Global Life Sciences conference in New York. Kensey Nash is a small company developing biomaterials for a number of applications, from wound closure and drug delivery to orthopaedics, focussing on markets with a total potential of over $2 billion.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel